ES2678144T3 - Composiciones relacionadas con SAH y métodos de uso - Google Patents

Composiciones relacionadas con SAH y métodos de uso Download PDF

Info

Publication number
ES2678144T3
ES2678144T3 ES11745103T ES11745103T ES2678144T3 ES 2678144 T3 ES2678144 T3 ES 2678144T3 ES 11745103 T ES11745103 T ES 11745103T ES 11745103 T ES11745103 T ES 11745103T ES 2678144 T3 ES2678144 T3 ES 2678144T3
Authority
ES
Spain
Prior art keywords
remainder
sah
residue
amino acid
acid substitutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11745103T
Other languages
English (en)
Inventor
Changshou Gao
Chaity Chaudhury
Xiaotao Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Application granted granted Critical
Publication of ES2678144T3 publication Critical patent/ES2678144T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un polipéptido que comprende una parte de seroalbúmina humana (SAH), cuya parte de SAH comprende el dominio III de SAH o un fragmento de unión al receptor Fc neonatal (FcRn) del mismo, en el que: el dominio III de SAH comprende una o más sustituciones de aminoácido en cualquiera de las siguientes posiciones, numeradas respecto a la posición en la SAH madura de longitud completa (SEQ ID NO: 2): resto 407, resto 415, resto 424, resto 426, resto 463, resto 506, resto 508, resto 509, resto 511, resto 512, resto 515, resto 521, resto 523, resto 524, resto 526, resto 535 y resto 557; la una o más sustituciones de aminoácido aumentan una o ambas de la afinidad por FcRn y semivida en suero del polipéptido respecto a un polipéptido de control en que la parte de SAH no incluye dichas sustituciones de aminoácido; y en el que, las sustituciones de aminoácido en la posición 506 se seleccionan de T506F, T506W, T506Y; las sustituciones de aminoácido en la posición 508 se seleccionan de T508K, T508R, T508S; y las sustituciones de aminoácido en la posición 535 se seleccionan de H535D, H535E, H535P.
ES11745103T 2010-02-16 2011-02-15 Composiciones relacionadas con SAH y métodos de uso Active ES2678144T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30495410P 2010-02-16 2010-02-16
US36450310P 2010-07-15 2010-07-15
PCT/US2011/024855 WO2011103076A1 (en) 2010-02-16 2011-02-15 Hsa-related compositions and methods of use

Publications (1)

Publication Number Publication Date
ES2678144T3 true ES2678144T3 (es) 2018-08-09

Family

ID=44483259

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11745103T Active ES2678144T3 (es) 2010-02-16 2011-02-15 Composiciones relacionadas con SAH y métodos de uso

Country Status (9)

Country Link
US (2) US8697650B2 (es)
EP (1) EP2536756B1 (es)
JP (1) JP2013519392A (es)
KR (1) KR20130020765A (es)
CN (2) CN102781960B (es)
AU (1) AU2011218294A1 (es)
CA (1) CA2789337A1 (es)
ES (1) ES2678144T3 (es)
WO (1) WO2011103076A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106986933A (zh) 2009-02-11 2017-07-28 阿尔布梅迪克斯医疗公司 白蛋白变体和缀合物
US8748380B2 (en) * 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
CN102781960B (zh) 2010-02-16 2014-12-10 米迪缪尼有限公司 Hsa相关组合物及使用方法
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
JP2014510518A (ja) * 2011-02-15 2014-05-01 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
CN104011072B (zh) * 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 白蛋白变体
BR112014008804A2 (pt) 2011-10-11 2017-06-13 Medimmune Llc suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos
EP2780364A2 (en) * 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
KR20140136934A (ko) 2012-03-16 2014-12-01 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
KR20150118123A (ko) * 2013-02-16 2015-10-21 노보자임스 바이오파마 디케이 에이/에스 약동학적 동물 모델
WO2014179657A1 (en) 2013-05-03 2014-11-06 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
CN105530948B (zh) * 2013-06-12 2023-05-26 法瑞斯生物技术有限公司 对天然cxcr4具有拮抗活性的肽
EP3063171B1 (en) * 2013-11-01 2019-07-24 University Of Oslo Albumin variants and uses thereof
US9751946B2 (en) 2014-09-12 2017-09-05 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
CA2957238C (en) 2014-09-12 2024-02-20 Genentech, Inc. Anti-her2 antibodies and immunoconjugates
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
CN107124870A (zh) 2014-09-17 2017-09-01 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物
CA2977675A1 (en) 2015-03-12 2016-09-15 Medimmune, Llc Method of purifying albumin-fusion proteins
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
CA3005953A1 (en) 2015-12-22 2017-06-29 Albumedix Ltd Improved protein expression strains
EP3394265A1 (en) 2015-12-23 2018-10-31 Biogen MA Inc. Dkk2 cysteine rich domain 2 containing proteins and uses thereof
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
CN110337590A (zh) 2016-11-04 2019-10-15 奥胡斯大学 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗
MX2019013919A (es) 2017-06-20 2020-01-21 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
ES2906997T3 (es) 2017-06-20 2022-04-21 Albumedix Ltd Cepas de expresión de proteínas mejoradas
JP2020537668A (ja) * 2017-10-18 2020-12-24 シーエスエル リミティド ヒト血清アルブミン変異体およびその使用
DK3717011T3 (da) 2017-11-29 2023-01-09 Csl Ltd Fremgangsmåde til behandling eller forebyggelse af iskæmi-reperfusionsskade
CN111712231A (zh) * 2018-02-23 2020-09-25 百多力股份公司 用于40-o-环状烃酯和相关结构的肠胃外制剂材料和方法
CN112118859A (zh) 2018-05-16 2020-12-22 杰特有限公司 1型可溶性补体受体变体及其用途
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2021536263A (ja) * 2018-09-07 2021-12-27 メディミューン，エルエルシー 細胞選択の方法
MX2021004772A (es) 2018-10-29 2021-08-16 Biogen Ma Inc Variantes de fc5 humanizado y estabilizado para mejorar el transporte de la barrera hematoencefalica.
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
KR20220058588A (ko) 2019-09-06 2022-05-09 노파르티스 아게 치료용 융합 단백질
US20230000774A1 (en) 2019-12-04 2023-01-05 Albumedix Limited Methods and compositions produced thereby
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
WO2024089258A1 (en) 2022-10-28 2024-05-02 Aarhus Universitet Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
GB9404270D0 (en) * 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20060051859A1 (en) 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
CA2625619A1 (en) 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CN106986933A (zh) 2009-02-11 2017-07-28 阿尔布梅迪克斯医疗公司 白蛋白变体和缀合物
EP2419120A4 (en) * 2009-04-08 2016-01-06 Univ California HUMAN PROTEIN CONCERNS WITH CONTROLLED SERUM PHARMACOKINETICS
AU2010276453A1 (en) 2009-07-20 2012-02-09 Dcb-Usa Llc Polypeptides selective for av beta3 integrin conjugated with a variant of human serum albumin (HSA) and pharmaceutical uses thereof
US8748380B2 (en) * 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
GB2476671B (en) 2010-01-04 2014-11-26 Plastic Logic Ltd Touch-sensing systems
CN102781960B (zh) 2010-02-16 2014-12-10 米迪缪尼有限公司 Hsa相关组合物及使用方法
WO2011124718A1 (en) * 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
JP5240316B2 (ja) 2010-10-26 2013-07-17 株式会社デンソー 車両乗員非操作運転システム
US20130225496A1 (en) * 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
JP2014510518A (ja) 2011-02-15 2014-05-01 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
KR20140035357A (ko) 2011-04-05 2014-03-21 셰브런 오로나이트 컴퍼니 엘엘씨 저점도 선박 실린더 윤활유 조성물
CN104011072B (zh) * 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 白蛋白变体

Also Published As

Publication number Publication date
EP2536756B1 (en) 2018-04-25
EP2536756A4 (en) 2013-08-14
AU2011218294A1 (en) 2012-08-30
US20130053322A1 (en) 2013-02-28
US20140248682A1 (en) 2014-09-04
JP2013519392A (ja) 2013-05-30
CA2789337A1 (en) 2011-08-25
WO2011103076A1 (en) 2011-08-25
EP2536756A1 (en) 2012-12-26
CN102781960B (zh) 2014-12-10
CN102781960A (zh) 2012-11-14
US9120875B2 (en) 2015-09-01
KR20130020765A (ko) 2013-02-28
CN104610454A (zh) 2015-05-13
US8697650B2 (en) 2014-04-15

Similar Documents

Publication Publication Date Title
ES2678144T3 (es) Composiciones relacionadas con SAH y métodos de uso
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
BR112015024587A2 (pt) variante de região fc
BR112014019901A2 (pt) proteínas de fator viii recombinante
PH12014501602B1 (en) Chimeric factor viii polypeptides and uses thereof
EA201291362A1 (ru) Слитый белок против злокачественных новообразований
BR112013026828A2 (pt) polipeptídeos de anticorpo que antagonizam cd40
UA111818C2 (uk) Антитіло проти csf-1r
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
NZ606584A (en) Binding proteins for hepcidin
PH12014501924A1 (en) Xten conjugate compositions and methods of making same
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
GB201009493D0 (en) Modified recombinant factor viii and von willebrand factor and methods of use
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
WO2014004336A3 (en) Split inteins, conjugates and uses thereof
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
NZ630484A (en) Compositions and methods for treatment of metabolic disorders and diseases
EA201170879A1 (ru) Полипептиды с ксиланазной активностью
UA108778C2 (xx) Протираковий злитий протеїн
PL397595A1 (pl) Przeciwnowotworowe bialko fuzyjne
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.